Role of FDG-PET in the assessment of survival prognosis in melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 6, 2007, Pages 740-747

  Pleiss, Christiane ^a   Risse, Jörn H ^a   Biersack, Hans Jürgen ^a   Bender, Hans ^b  

^a UNIVERSITY OF BONN   (Germany)

^b Roentgeninstitut Düsseldorf ^*  (Germany)

Author keywords

FDG PET melanoma; Positron emission tomography; Staging; Survival prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TIME FACTORS; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 37549022217     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.356     Document Type: Article

References (23)

1. Balch CM, Reintgen DS, Kirkwood JM, et al. Cutaneous melanoma. In: Cancer - Principles and Practice of Oncology. 5th ed. DeVita VT, Hellman S, Rosenberg SA, eds, Lippincott-Raven, New York, 1997.
2. Holder WD, White RL, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764.
3. 18F-fluorodeoxyglucose positron emission tomography. Cancer 1998;82:1664
4. Steinert HC, Durband M, Böni R, et al. Outcome analysis in staging of malignant melanoma using FDG-PET versus conventional imaging: Influence on survival time in patients. J Nucl Med 1999;40:A79.
5. Kumar R, Alavi A. Clinical applications of fluorodeoxyglucose - positron-emission tomography in the management of malignant melanoma. Curr Opin Oncol 2005;17:154.
6. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)]F fluorodeoxyglucose-positron-emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006;13:525.
7. Kumar R, Chauhan A. Positron-emission tomography: Clinical applications in oncology. Part 2. Exp Rev Anticancer Ther 2006;6:625.
8. Bender H, Frohmann JP, Grapow M, et al. Value of whole-body FDG-PET in the routine staging of malignant melanoma. J Nucl Med 1997;A331:89P.
9. Ruhlmann JR, Oehr P, Biersack H-J, et al. FDG-PET compared to conventional diagnostic methods in malignant melanoma. J Nucl Med 1999;20P:78A.
10. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000;89:109.
11. Steinert H, Böni RAH, Buck A, et al. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology 1995;195:705.
12. Muller SP. Malignant melanoma: PET/CT as a staging procedure. Front Radiat Ther Oncol 2006;39:159.
13. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907.
14. Halfpenny W, Hain SF, Biassoni L, et al. FDG-PET: A possible prognostic factor in head and neck cancer. Br J Cancer 2002;86:512.
15. Bender H, Straehler-Pohl HJ, Kerling T, et al. Preoperative staging of head-and-neck tumors by FDG-PET: Impact of PET results on survival prognosis. Eur J Nucl Med 2003;30:A47.
16. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56.
17. Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutaneous melanoma. Am Cancer Soc 1997;80:1426.
18. Kazuyuki I, Toshiaki S, Akifumi Y. Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol 2001;6:109.
19. Balch CM, Soong S-J, Murad TM. A multifactoral analyses of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126.
20. Balch CM. A multifactorial analysis of melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193:377.
21. Homsi J, Kashani-Sabet M, Messina JL, et al. Cutaneous melanoma: Prognostic factors. Cancer Contr 2005;12(4):223.
22. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma: Analysis of 168 patients. Ann Surg 1990;212:173.
23. Bender H, Straehler-Pohl HJ, Risse HJ, et al. Clinical application of FDG-PET in the staging of selected tumors: Experiences and implications. In: Radionuclides for Oncology - Current Status and future aspects. Athens: Mediterra-Publishers, 1998.